idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
Phyton Biotech has successfully transferred the manufacturing process for the microbial production of Corallopyronin A (CorA). CorA is a novel anti-infective agent with the potential to address neglected tropical diseases. This achievement marks a significant step forward in the Company’s specialty GMP fermentation capabilities and supports the broader clinical development program led by the University Hospital Bonn (UKB), the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF).
CorA is a natural product anti-infective with a unique mechanism of action, showing potent activity against filarial infections such as river blindness (onchocerciasis) and lymphatic filariasis (LF), as well as against Staphylococci and the bacteria that cause community acquired pneumonia (CAP). The filarial infections are predominantly found in Africa (and in the case of LF, also in Asia), affect millions of people and are caused by parasitic worms that depend on bacterial symbionts. CorA selectively targets these symbionts, offering a promising therapeutic approach.
The technology transfer was successfully completed at the 1,500 L scale at Phyton Biotech’s GMP facilities near Hamburg, Germany (Fermentation) and in Vancouver, Canada (Purification). Key outcomes include:
• Robust fermentation of the genetically engineered Myxococcus xanthus strain.
• Efficient cell separation using tangential flow filtration (TFF).
• High-yield resin capture and purification of CorA, meeting all critical quality attributes.
"Completing the Corallopyronin A technology transfer marks an important milestone for Phyton Biotech and our partners," said Colin Marr, President of Phyton Biotech. "It highlights our comprehensive fermentation expertise including organism classes not broadly used in industry and our ability to support the scale-up of this novel therapy for clinical evaluation."
With the initial transfer process now complete, Phyton Biotech is preparing to demonstrate scalability and process performance at the 7,500 L scale to supply GMP quality CorA for upcoming clinical trials.
This project is part of a broader international collaboration supported by the DZIF and the Global Health Innovative Technology (GHIT) Fund from Japan through collaboration with the Japanese pharmaceutical company, Eisai Co. Ltd., aiming to advance CorA as a new treatment option for diseases that disproportionately affect underserved populations. Prof. Achim Hoerauf, principal investigator of the CorA development consortium and Director of the Institute of Medical Microbiology, Immunology and Parasitology at the University Hospital Bonn, emphasizes the importance of the DZIF and GHIT Fund in enabling the project to meet high international standards in preclinical development. "Through the DZIF and GHIT Fund, we were able to implement these standards within a consortium of academic institutions working alongside industrial partners—an achievement that would normally take many years," says Hoerauf, who is also deputy coordinator of the DZIF research area "Malaria and Neglected Tropical Diseases".
The DZIF’s broad spectrum of expertise was key to the project’s success: the optimized heterologous production strain was developed at HZI under the leadership of DZIF scientist Prof. Rolf Müller. The production process, consisting of fermentation and purification, was also established at the HZI in the working group of Prof. Marc Stadler, deputy coordinator of the DZIF research area "Novel Antibiotics", and accompanied during the technology transfer. The orally administered formulations were developed in Bonn under the direction of DZIF scientist Prof. Karl Wagner (with support from ForTra gGmbH for Research Transfer of the Else Kröner Fresenius Foundation). The formulations will now be used in upcoming clinical trials.
The press release is available in German at this link: https://idw-online.de/de/news865616
Prof. Dr. Achim Hörauf
University Hospital Bonn
achim.hoerauf@ukbonn.de
https://phytonbiotech.com/phyton-biotech-completes-corallopyronin-a-technology-t... Press release of Phyton Biotech
https://www.dzif.de/en/corallopyronin-new-antibiotic-against-worm-infections Further information on Corallopyronin A
https://www.dzif.de/en/malaria-and-neglected-tropical-diseases DZIF research"Malaria and Neglected Tropical Diseases"
https://www.dzif.de/en/novel-antibiotics DZIF research area "Novel Antibiotics"
Bioreactors for the production of Corallopyronin A at the HZI's Biotechnikum in Braunschweig.
Copyright: HZI/Frank Surup
Criteria of this press release:
Business and commerce, Journalists, Scientists and scholars, all interested persons
Biology, Medicine
transregional, national
Cooperation agreements, Transfer of Science or Research
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
